GATC Health engages Dr. Chad Beyer to head IND-enabling studies for its AI-generated Opioid Use Disorder drug candidate

An addiction medicine expert with more than 30 IND filings and two FDA successes, Dr. Beyer will help to advance GATC compounds to human clinical trials. IRVINE, Calif., May 30, 2024 /PRNewswire/ — GATC Health Corp, a technology company advancing drug discovery and disease prediction…